Keystone Heart

Embolic Cerebral Protection Devices

Health Tech & Life Sciences
Acquired (Inactive) by Venus Medtech on Dec 2018 - closed due to acquisition

Company Overview

Snapshot

Founded in November 2004, Keystone Heart operates with 11–50 employees. The company was acquired by Venus Medtech in December 2018, marking a significant milestone in its journey to develop cerebral embolic protection devices.

Business overview

Keystone Heart is a medical device company focused on developing and manufacturing cerebral embolic protection devices. Its core technology aims to reduce the risk of stroke, neurocognitive decline, and dementia caused by brain emboli during cardiovascular procedures such as TAVR, surgical valve replacement, and atrial fibrillation ablation. The company's TriGuard product pipeline is designed to preserve brain reserve in patients undergoing these procedures, serving interventional cardiologists, electrophysiologists, and cardiac surgeons in the healthcare industry.

Strategic signal

In June 2020, Keystone Heart, operating as a Venus Medtech company, acquired 510 Kardiac Devices, Inc. This acquisition signals a strategic move to expand its product portfolio and market reach within the medical device sector, reinforcing its commitment to innovation in cardiovascular care.

Company Intelligence Q&A

When was Keystone Heart acquired?
Keystone Heart was acquired by Venus Medtech in December 2018.
What was a key partnership for Keystone Heart in Asian markets?
In March 2017, Keystone Heart announced a partnership with Venus Medtech for cerebral embolic protection with transcatheter heart valve systems (TAVR) in China and other key Asian markets.
When did Keystone Heart begin a Phase II trial for its TriGUARD 3 device?
Keystone Heart began a Phase II trial for its TriGUARD 3 device in June 2018, with the first enrollment announced in May 2018.
What was a significant product development for Keystone Heart in 2020?
In March 2020, Keystone Heart secured CE Mark approval for its cerebral embolic protection device, followed by the first commercial case performed worldwide with the TriGUARD 3 Cerebral Embolic Protection Device in July 2020.
Which company did Keystone Heart acquire as a Venus Medtech company?
In June 2020, Keystone Heart, as a Venus Medtech company, acquired 510 Kardiac Devices, Inc.

External links